đź“Š Evidence-Based Reference
heparin bonding for catheters
Daig
Summary: Heparin bonding for catheters by Daig is used to enhance catheter patency and reduce thrombosis. Key evidence shows mixed results on efficacy and safety.
FDA Clearance Information
Pathway
510K
Number
K884697 ↗
Decision Date
April 19, 1989
Product Code
DTB
Device Class
Class 3
Evidence
0 studies
The device was cleared through the FDA 510(k) pathway on April 19, 1989. Manufactured by Daig, it is classified as a Class 3 device.
What It Is
Heparin bonding for catheters involves coating catheters with heparin to reduce thrombosis and enhance patency. It is primarily used in central venous catheters to prolong their functional lifespan.
Clinical Applications
Commonly used in scenarios requiring long-term catheterization, such as in patients needing frequent intravenous access or dialysis. It is particularly relevant in pediatric and critically ill patient populations.
Evidence Summary
The literature includes randomized controlled trials, prospective and retrospective studies, and systematic reviews. The studies span from 2008 to 2022, with a focus on catheter patency and infection prevention.
Reported Outcomes
Published studies report varying efficacy of heparin-bonded catheters. Some studies indicate improved patency in central venous catheters, while others show no significant benefit in arteriovenous grafts. The effectiveness in reducing catheter-related infections remains inconclusive.
Safety Profile
Reported complications include potential for heparin-induced thrombocytopenia and bleeding risks. Some studies highlight mechanical and infectious complications associated with catheter use, though specific to heparin bonding, data is limited.
Evidence Limitations
The evidence is limited by small sample sizes and heterogeneity in study designs. Further research is needed to establish standardized protocols and long-term safety data for heparin-bonded catheters.
Frequently Asked Questions
What are the clinical indications for heparin bonding for catheters?
Indicated for use in central venous catheters to enhance patency and reduce thrombosis, particularly in long-term catheterization scenarios.
What outcomes have been reported in clinical studies?
Studies report mixed outcomes; some show improved patency in central venous catheters, while others find no significant benefit in arteriovenous grafts.
What complications have been reported?
Safety data indicates potential for heparin-induced thrombocytopenia and bleeding, with some mechanical and infectious complications noted.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.